Abstract

Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol

Author(s): Snyder Scott, Listecki Robert E

Issue: Sep/Oct 2012 - Volume 16, Number 5

Page(s): 376-380

Download in electronic PDF format for $75
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 1
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 2
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 3
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 4
  • Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Page 5

Note: Electronic version includes supplemental material.

Abstract

Effective thyroid replacement therapy may be elusive to some patients, and compounding pharmacists have an opportunity to deliver more effective therapy. Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th edition states that the body usually secretes T4:T3 in an 11:1 ratio but cautions against pursuing combined thyroid replacement due to the short halflife of T3 that necessitates multiple daily dosing; no commercial availability and lack of benefit were shown in trials.1 Commercial combinations of T4/T3 such as Armour Thyroid and Nature-Thyroid have a 4.22:1 T4:T3 ratio. Applying the same concept as bioidentical hormone replacement therapy, compounding pharmacists can deliver an 11:1 ratio using a commercial T4 product and taking into account oral bioavailability of each entity. The short half-life of T3 can be remedied by taking the patient’s daily T3 dose and dividing it into two slow-release capsules to be dosed every 12 hours.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2012
Pg. 376-380
Jul/Aug 2005
Pg. 268-273
Author(s): Milner Martin
Sep/Oct 2017
Pg. 418-425
Nov/Dec 2008
Pg. 545
Author(s): Allen Loyd V Jr
Jul/Aug 2010
Pg. 306-309
Author(s): Stack Bob
Jan/Feb 2023
Pg. 22-23
Author(s): Brunner Scott
Mar/Apr 2010
Pg. 165-170
Nov/Dec 2008
Pg. 547
Author(s): Allen Loyd V Jr
Nov/Dec 2008
Pg. 548
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 250-256
Jan/Feb 2002
Pg. 50-54
Author(s): Wepfer Scott T
Nov/Dec 2008
Pg. 488-497
Author(s): Paoletti Jim
Jan/Feb 2024
Pg. 34-43
Author(s): Paoletti Jim
Jan/Feb 2001
Pg. 52-54
Author(s): Ford Gina, Garcia Lea
Mar/Apr 2002
Pg. 142-146
Author(s): Wepfer Scott T
Jul/Aug 2004
Pg. 313-319
Jul/Aug 2005
Pg. 266
Author(s): White Irene Q
Nov/Dec 2016
Pg. 447-454
Author(s): Deleruyelle Laura J
Sep/Oct 2016
Pg. 359-364
Author(s): Deleruyelle Laura J
Jul/Aug 2011
Pg. 290-300